OBJECTIVE: To determine the relationship between changes in antibody levels towards citrullinated peptides derived from different candidate autoantigens and therapeutic outcome in early @entity309 ( @entity309 ). METHODS: Baseline and 3-month serum samples from 316 @entity1 with early @entity309 enrolled in the Swedish Farmacotherapy (SWEFOT) trial were analysed for antibodies against cyclic citrullinated peptides (CCP) and citrullinated peptides derived from vimentin (cVim), @entity2002 (cFib) and a-enolase ( @entity5809 ). At 3-month follow-up, @entity1499 monotherapy-inadequate responders were randomised to add-on therapy with @entity3378 and @entity6383 or infliximab. In these patients, anticitrullinated peptide antibodies (ACPA) were also assessed at 12 and 24   months. The proportion of antibody-positive @entity1 and relative changes in antibody levels were compared across ACPA specificities and related to therapeutic response and radiographic progression. RESULTS: During the 2-year follow-up, the proportion of @entity1 testing positive declined significantly regarding antibodies to cVim, cFib and @entity5809 , while anti-CCP antibody occurrence remained stable over time. Turning anti-cVim antibody negative was most common, and anti-cVim antibody seroreversion during the first three   months associated with significantly less 2-year radiographic progression compared with @entity1 who remained positive. Median antibody levels of all tested ACPAs declined uniformly during initial methotrexate therapy and following response to add-on therapy, with no significant relation to treatment regimen or radiographic progression. CONCLUSIONS: The influence of early antirheumatic therapy on ACPA seroreversions was markedly different across specificities, and early disappearance of anti-cVim antibodies associated with better radiological outcome. Thus, these data suggest that the disappearance of particular ACPA reactivities may be @entity309 . TRIAL REGISTRATION NUMBER: WHO database at the Karolinska institute: CT20080004; and clinicaltrials.gov: NCT00764725.

Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early XXXX : results from the SWEFOT trial.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2002 :: ('2244', 'Gene') :: ['fibrinogen'] @entity5809 :: ('11064', 'Gene') :: ['CEP-1'] @entity6383 :: ('MESH:D006886', 'Chemical') :: ['hydroxychloroquine'] @entity3378 :: ('MESH:D012460', 'Chemical') :: ['sulfasalazine'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate'] @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'RA', 'beneficial in early RA']
@entity309 :: (MESH:D001172,Disease) :: ['rheumatoid arthritis']
